← Back to Screener
Seaport Therapeutics, Inc. Common Stock (SPTX)
Price$17.13
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (4W)-13.29%
VGM Score66.59
All Metrics
Price vs S&P 500 (YTD)-13.29%
10-Day Avg Trading Volume0.26M
3-Month Avg Trading Volume0.59M
52-Week High$23.00
Year-to-Date Return-8.32%
5-Day Price Return3.94%
Month-to-Date Return-8.32%
Beta-10.51x
52-Week Low$14.85
mGradeB
vgmGradeB
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | B | $17.13 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.